Register

Lupus

Patients with type 2 SLE present with fatigue, pain, brain fog and mood changes. Type 1 & 2 often coexist but type 2 SLE impacts QOL. @RheumNow #lupus #APLAR2026 https://t.co/aMtoIprPWG

https://x.com/RHEUMarampa/status/2115970283438051839/photo/1

“Complex to manage” in SLE not for biologics APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs

https://x.com/drpnash/status/2115998694860574864/photo/1

why biologics for “refractory”only - a life on steroids HCO MMF etc? APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/Fa58nsF5Mk

https://x.com/drpnash/status/2115997515338379749/photo/1

Prof. Sandra Navarra on GCs in #lupus : “There is NO safe threshold for Prednisone” Pred use follows a linear risk: As the dose of prednisone increases, damage risk doubles - - - > higher cataract, fracture and CV risks! @RheumNow #APLAR2026 https://t.co/8GGrwkcd8Q

evidence T2T in SLE is wortwhile APLAR Seoul 2026 Nikpour #SLE #RheumNow

Saag Osteoporosis - what to do when stopping Denosumab ? APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/skeONgWUpH

https://x.com/drpnash/status/2115999992028807378/photo/1

Schett - in remission : 14 normal pregnancies no SLE recurrence , babies normal b cells APLAR Seoul 2026 #CART #RheumNow

Cutaneous #lupus are classified into: acute, subacute and chronic. Acute CLE is highly assoc’d w/ photosensitivity, +ANA and systemic involvement. Chronic CLE develops scarring and pigmentation CLE is an initial manifestation of SLE in 25% of pts @RheumNow #APLAR2026 https://t.co/4GdyUuqlzH

https://x.com/RHEUMarampa/status/2116000143610904835/photo/1

Advances and Challenges in Lupus Care: Insights https://t.co/qQ0kk3W80C https://t.co/xMCtvMKIem

Advances and Challenges in Lupus Care: Insights | RheumNow

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested. https://t.co/g6BvYuBzVj

Article

The Efficacy of Ianalumab in Sjögren’s Disease

Jack Cush, MD Oct 28, 2026

The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.

CLARITY-1 & CLARITY-2 Phase 3 Trials show Brepocitinib effective in Non-Infectious Uveitis. 371 pts Rx w. brepocitinib 45 mg or placebo x48wks w/ 2 wks of Pred taper. Time to Rx failure greater w/ BREP (48 vs 12 wks PBO; p<0.0001)https://t.co/EBaWe7TJbt https://t.co/UVg188eEHZ

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase…

Article

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk

MedPage Today Oct 27, 2026

Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.

Rheum Survey on SCLE> In your clinic, what is the most common cause of drug-induced subacute cutaneous lupus (SCLE). CLICK HERE>> https://t.co/LdnYIw0Qw3 https://t.co/qWUqwFpLta

Survey Result | RheumNow

Two crystals in one joint? Cryptococcus risk doubled with JAK inhibitors? And early damage in Sjögren’s linked to a 12–14-fold increase in lymphoma risk? Dr. Jack Cush breaks down the findings behind the numbers in this week's RheumNow roundup: - JAK inhibitors: Cryptococcal https://t.co/4RkznhyoIt

Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. https://t.co/U28aBsQpJ8 https://t.co/g9Ak2MCJEN

https://buff.ly/S1ss5wm

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c

van Vollenhoven’s Treatment Advances in Lupus Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase. https://t.co/5oCf60XmuJ https://t.co/8TGC1Y4Cqp

van Vollenhoven’s Treatment Advances in Lupus | RheumNow

Should You Use Low Dose Naltrexone? A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/sC7kteQVMZ

FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study https://t.co/n9wO2wLLBk https://t.co/E0kL3j931Z

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus | NeurologyLiv…

Joint Disease in SLE Reconsidered A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x

RheumNow Live 2027 registration is NOW OPEN. GLP-1s in your clinic. CAR-T in lupus. Rheumatology experts vs. AI, with your vote. Jan. 30–31 | Onsite + virtual Early Bird Pricing through 12/15/2026. See the agenda. Register: https://t.co/zYYC2350tE https://t.co/QeSxDPlIpv

RheumNow

RHEUMATOLOGIST Survey Q: How do you assess cutaneous lupus activity or treatment responses? CLICK HERE> https://t.co/PZDVpkqR1q https://t.co/bAQ7qNqGIA

Survey Result | RheumNow

Tis the Season for Vaccination Vaccination is essential for all rheumatologic patients, but particularly for patients on glucocorticoids and immunosuppression who face increased risk from infectious diseases. https://t.co/hHx1okkwHD https://t.co/nzRa9pzQ1X

‘Tis the Season for Vaccination | RheumNow

Novel Imaging of Skin Disease in Scleroderma An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study. https://t.co/vHmxD1cHRR https://t.co/BWW6Te9FFI

Novel Imaging of Skin Disease in Scleroderma | RheumNow

Therapeutic Updates

Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis

Sponsored by Aurinia

Apr 17, 2026

Aurinia 2026 May RX Update

Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.

Navigating the Path to SLE Remission

Sponsored by AstraZeneca Medical Affairs

Aug 01, 2025

Watch rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice.

Lupus Nephritis

Sponsored by RheumNow

Apr 30, 2025

Management of CKD in Lupus Nephritis Patients

View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.

How well do you know this week's rheumatology news?

Take the rheumIQ quiz

Take the RheumIQ Quiz

Daily Download

GLP-1 Receptor Agonists in Rheumatology

Obesity GLP cover image

Download See More Resources

Podcasts

Day 4 Recap EULAR 2026
Jun 06, 2026
EULAR 2026 Daily Podcast Day 2c
Jun 05, 2026
EULAR 2026 Daily Podcast Day 1a
Jun 03, 2026

Topic Videos

×